comparemela.com
Home
Live Updates
F. Hoffmann-La Roche Ltd: FDA grants Priority Review to Roches Lunsumio for people with relapsed or refractory follicular lymphoma : comparemela.com
F. Hoffmann-La Roche Ltd: FDA grants Priority Review to Roche's Lunsumio for people with relapsed or refractory follicular lymphoma
Lunsumio (mosunetuzumab) could be the first CD20xCD3 T-cell engaging bispecific antibody approved by the FDA for the treatment of any type of non-Hodgkin lymphoma Application is based on results from the
Related Keywords
Japan ,
United States ,
Switzerland ,
America ,
American ,
Nathalie Meetz ,
Birgit Masjost ,
Levi Garraway ,
Loren Kalm ,
Sabine Borngr ,
Gerard Tobin ,
Bruno Eschli ,
Genentech ,
European Commission ,
Drug Administration ,
Head Of Global Product Development ,
American Society Of Hematology ,
Roche Group ,
Roche Group Media Relations ,
Biologics License Application ,
Priority Review ,
Chief Medical Officer ,
Global Product ,
American Society ,
Annual Meeting ,
Breakthrough Therapy ,
Orphan Drug Designation ,
Dow Jones Sustainability Indices ,
Chugai Pharmaceutical ,
Hoffmann ,
Oche ,
Migrants ,
Priority ,
Review ,
Lunsumio ,
People ,
Relapsed ,
Refractory ,
Follicular ,
Lymphoma ,
comparemela.com © 2020. All Rights Reserved.